Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2023 Earnings Call Transcript

Richard Miller: Okay. Thanks, Roger. The first — the answer to the first part — the first question is, from a regulatory perspective, protocol, all that sort of stuff, everything is complete. The reason — it takes a few months to complete protocols to get through IRBs. Most institutions now not only have an IRB, they have a research committee. So that’s just the paperwork of getting through these centers. We’re not anticipating any problem. Most of these institutions now will not evaluate. They will not consider a study unless it has been gone through the FDA approval process, and we’ve done that. So really, there’s really no hurdles with respect to getting the study going. And as I mentioned, we have had a very good response to people who want to be involved in the study, really the best people in the country. And I’ll let Leiv answer the second question?

Leiv Lea : So Roger, we know we’re going to need to raise additional capital. However, we’re very excited about the broad potential of soquelitinib in both oncology and inflammatory and immune-mediated diseases. Thus, as Richard mentioned, it opens up partnering opportunities for us. We believe our pipeline of novel products that address large markets and diverse areas of cancer and immune disease will enable us to finance Corvus to benefit both the company and its stockholders. So we like our product candidates. So very excited about soquelitinib, and we’ll finance the company as appropriate to benefit both for the company and the stockholders.

Roger Song: Yeah, that make sense. Thanks for taking the question.

Richard Miller: All right. I think, I don’t see any more questions. So I want to thank everyone for participating in the call. We look forward to updating you on our future progress. Thanks, everyone.

Operator: This concludes today’s conference. You may disconnect your lines at this time, and we thank you for your participation.